Literature DB >> 15657660

Specific enhanced expression of platelet-derived endothelial cell growth factor in submucosa of human colorectal cancer.

Tadashi Nozawa1, Takumo Enomoto, Yoshitomo Koshida, Yuichi Sato, Masaru Kuranami.   

Abstract

PURPOSE: Platelet-derived endothelial cell growth factor, identified to be an angiogenic factor, has been implicated in metastases of colorectal cancer. This study aimed to clarify the role and localization of platelet-derived endothelial cell growth factor associated with human colorectal cancer invasion.
METHODS: Thirty-two patients with colorectal cancer who had undergone surgery were analyzed. Platelet-derived endothelial cell growth factor enzyme activities in the colorectal cancer specimens were measured. Cells that expressed platelet-derived endothelial cell growth factor were identified and localized by immunohistochemical analysis with anti-human platelet-derived endothelial cell growth factor antibody and by in situ hybridization with specific RNA probe.
RESULTS: Platelet-derived endothelial cell growth factor enzyme activity increased significantly in cancer tissues compared with normal colonic mucosa at various distances from the cancer. Immunohistochemical analysis and in situ hybridization demonstrated platelet-derived endothelial cell growth factor expression in stromal macrophages and fibroblasts located in cancer tissues and surrounding noncancerous tissues, although the tumor cells and normal colonic mucosa were negative. The value of platelet-derived endothelial cell growth factor expression was highest at the border of the colorectal cancer (35.3 +/- 8.9 percent), followed by the cancer nest (15.2 +/- 9.2 percent) and normal mucosa (7.7 +/- 3.4 percent). In the border area, the highest value of platelet-derived endothelial cell growth factor expression was observed in the submucosa (35.3 +/- 8.9 percent), followed by the muscular propria (21.9 +/- 7.7 percent) and the subserosa (14.9 +/- 5.5 percent).
CONCLUSIONS: Stromal macrophages and fibroblasts are responsible for elevated platelet-derived endothelial cell growth factor activity in colorectal cancer. The significance of enhanced expression of platelet-derived endothelial cell growth factor in the submucosa at the cancer border remains unclear. Cancer stroma may be an important factor for cancer angiogenesis and may serve as a treatment target through specific modulation of angiogenic factors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15657660     DOI: 10.1007/s10350-004-0712-y

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  5 in total

1.  C936T polymorphism of the VEGF gene in relation to the risk and the clinical and biological characteristics of sporadic colorectal adenocarcinoma.

Authors:  Laura Credidio; Carmen Silvia Passos Lima; Raquel Leal; Maria Lourdes S de Ayrizono; João José Fagundes; Luis Alberto Magna; Claudio Saddy Rodrigues Coy
Journal:  BMC Res Notes       Date:  2014-10-31

2.  Thymidine phosphorylase expression and prognosis in colorectal cancer treated with 5-fluorouracil-based chemotherapy: A meta-analysis.

Authors:  Jia Che; Lun Pan; Xiangling Yang; Zhiting Liu; Lanlan Huang; Chuangyu Wen; Aihua Lin; Huanliang Liu
Journal:  Mol Clin Oncol       Date:  2017-10-03

3.  Thymidine Phosphorylase Gene Expression in Stage III Colorectal Cancer.

Authors:  Elinor B Lindskog; Yvonne Wettergren; Elisabeth Odin; Bengt Gustavsson; Kristoffer Derwinger
Journal:  Clin Med Insights Oncol       Date:  2012-10-15

4.  Thymidine phosphorylase expression is associated with time to progression in patients with metastatic colorectal cancer.

Authors:  Elinor Bexe Lindskog; Kristoffer Derwinger; Bengt Gustavsson; Peter Falk; Yvonne Wettergren
Journal:  BMC Clin Pathol       Date:  2014-06-10

5.  Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from colorectal cancer: a case-control study from a Chinese center.

Authors:  Chao-Qun Huang; Jue-Ping Feng; Xiao-Jun Yang; Yan Li
Journal:  J Surg Oncol       Date:  2013-12-27       Impact factor: 3.454

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.